NewAmsterdam Pharma (NAMSW) Projected to Post Quarterly Earnings on Thursday

NewAmsterdam Pharma (NASDAQ:NAMSW) will likely be issuing its resultson Thursday, May 7th. Analysts expect the company to announce earnings of ($0.4851) per share and revenue of $1.0930 million for the quarter.

NewAmsterdam Pharma Stock Up 12.6%

Shares of NAMSW stock opened at $19.71 on Tuesday. NewAmsterdam Pharma has a fifty-two week low of $7.16 and a fifty-two week high of $29.99. The stock’s 50-day moving average is $21.16 and its two-hundred day moving average is $23.43.

Institutional Trading of NewAmsterdam Pharma

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.